Asked by: Mochan, Carol (Scottish Labour - South Scotland)
Question
To ask the Scottish Government what recent preventative spend projects it has invested in, following the recommendations from the Accelerated National Innovation Adoption Pathway programme.
Answered by Gray, Neil - Cabinet Secretary for NHS Recovery, Health and Social Care
The Scottish Government is committed to unlocking the potential of scientific and technological innovation to transform lives, increase healthy life expectancy and reduce health inequalities across Scotland.
The Accelerated National Innovation Adoption (ANIA) pathway has been established to provide a national approach to the identification and adoption of research proven scientific and technological innovations. The ANIA pathway is led by the Centre for Sustainable Delivery, hosted by NHS Golden Jubilee. It is a collaborative venture that also draws on the expertise of NHS National Services Scotland, Healthcare Improvement Scotland, Public Health Scotland and NHS Education for Scotland.
The ANIA pathway is governed by an Innovation Design Authority (IDA). This brings together senior Scottish Government and NHS leadership to support improved partnership working, provide system leadership and take joint decisions on the progression of innovations through ANIA stage gates.
Following recommendations from the IDA, the Scottish Government has:
There are a range of further innovations currently being evaluated within the ANIA pathway. Scottish Ministers will consider investment in these programmes following any recommendation by the IDA.
Mentions:
1: Lee Anderson (RUK - Ashfield) What steps she is taking to tackle medicine shortages for type 2 diabetes. - Speech Link
2: Andrew Stephenson (Con - Pendle) The Department has been working with the suppliers of medicines used in the treatment of type 2 diabetes - Speech Link
3: Lee Anderson (RUK - Ashfield) country is costing the NHS about £20 billion a year, and it is a major contributory factor to type 2 diabetes - Speech Link
4: Andrew Stephenson (Con - Pendle) Obesity is linked to many health conditions, including type 2 diabetes. - Speech Link
5: Andrew Stephenson (Con - Pendle) We all know that diabetes medicine shortages are a global issue affecting countries not just across the - Speech Link
Apr. 22 2024
Source Page: Quality Prescribing Strategy for Respiratory A Guide for Improvement 2024-2027Found: and Therapeutics Division, Scottish Government Bryony Murray Senior Policy Officer, Respiratory and Diabetes
Apr. 22 2024
Source Page: I. List of ministerial responsibilities. 88p. II. List of non-ministerial departments and executive agencies. 22p. III. Letter dated 19/04/2024 from Alex Burghart MP to the Public Administration and Constitutional Affairs Committee regarding documents for deposit, and copying them for deposit in the House libraries. 1p.Found: elective care recovery ○ hospital reconfigurations ○ special measures regimes ● Major diseases ○ cancer ○ diabetes
Mentions:
1: Chris Stephens (SNP - Glasgow South West) disproportionately by much higher rates of food-related ill health and disease, from obesity to type 2 diabetes - Speech Link
Asked by: Ashley Dalton (Labour - West Lancashire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the guidance submitted to medical professions on the prescription of semaglutide on the availability of that drug for people suffering from type 2 diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.
We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.
Asked by: Ashley Dalton (Labour - West Lancashire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is working with her international counterparts to tackle supply issues relating to (a) semaglutide and (b) other glucagon-like peptide-1 receptor agonists licensed for treating patients with type 2 diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.
We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.
Asked by: Ashley Dalton (Labour - West Lancashire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking with pharmaceutical companies to increase the supply of semaglutide.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.
We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.
Apr. 19 2024
Source Page: Scotland's Genomic Medicine Strategy 2024-2029Found: conditions People with Friedreich’s ataxia are at increased risk of cardiomyopathy, cardiac arrhythmias and diabetes
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to NHS England's web page entitled Diabetes treatment and care programme, whether all eight Type 1 diabetes and disordered eating pilots have been commissioned by their Integrated Care Systems to secure services independently of NHS England pilot scheme funding.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The national approach to funding the establishment of Type 1 Diabetes with Disordered Eating services was delivered in two phases. Initial sites in London, Hampshire, and Dorset received national funding between 2018/19 and 2021/22, before the transition of commissioning responsibility to local systems commenced from April 2023. All three of these services did initially secure local funding, independent of the national pilot scheme. More recently, we understand that the status of these sites to be as follows: London services are partially active across London, with local consideration of ongoing funding and delivery arrangements underway; Hampshire services are active and embedded in wider eating disorder specialist services; and Dorset services have been discontinued. The remaining five newer services have been funded from September 2022, and are nationally funded up to March 2025.